Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | ADCE-D01 |
| Synonyms | |
| Therapy Description |
ADCE-D01 is an antibody-drug conjugate (ADC) comprising a monoclonal antibody targeting uPARAP (MRC2) linked to P-1021, which potentially induces DNA damage and tumor cell death (Cancer Res (2025) 85 (8_Supplement_1): 4784). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| ADCE-D01 | ADCED01|ADCE D01 | ADCE-D01 is an antibody-drug conjugate (ADC) comprising a monoclonal antibody targeting uPARAP (MRC2) linked to P-1021, which potentially induces DNA damage and tumor cell death (Cancer Res (2025) 85 (8_Supplement_1): 4784). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06797999 | Phase Ib/II | ADCE-D01 | First-in-Human Study of ADCE-D01 in Soft Tissue Sarcoma (ADCElerate1) | Recruiting | USA | GBR | FRA | DEU | BEL | 0 |